ライフサイエンスコーパス: multiorgan failure

1 chemotherapy died of toxicity (infectious or multiorgan failure).

2 nvestigator (pneumonia, and septic shock and multiorgan failure).

3 increasing acute phase reactants tests, and multiorgan failure.

4 th included sepsis, right heart failure, and multiorgan failure.

5 ly but died in the postoperative period from multiorgan failure.

6 y ET and suggest that it causes death due to multiorgan failure.

7 teremia, systemic inflammatory response, and multiorgan failure.

8 thrombocytopenia, Aspergillus infection, and multiorgan failure.

9 Of these seven deaths, all were related to multiorgan failure.

10 ly four (12%) of these patients died, all of multiorgan failure.

11 e release rapidly leading to respiratory and multiorgan failure.

12 on, and those with burn-associated sepsis or multiorgan failure.

13 ia, acute respiratory distress syndrome, and multiorgan failure.

14 D with subsequent respiratory compromise and multiorgan failure.

15 A fifth patient died from multiorgan failure.

16 ectrum antibiotics, she ultimately died from multiorgan failure.

17 minal hypotension, respiratory distress, and multiorgan failure.

18 ning acute respiratory distress syndrome and multiorgan failure.

19 h in vascular integrity, cytokine storm, and multiorgan failure.

20 similarly effective (AUC 0.85) at predicting multiorgan failure.

21 ungs, hearts, and other organs, resulting in multiorgan failure.

22 group and 4 in the surgical group developed multiorgan failure.

23 gn and evaluation for use after the onset of multiorgan failure.

24 herapeutic implications in human AKI-ALI and multiorgan failure.

25 mic inflammation and coagulation, leading to multiorgan failure.

26 opment of acute-on-chronic liver failure and multiorgan failure.

27 ude hemorrhage, endothelial dysfunction, and multiorgan failure.

28 s from 0, normal, to 24, most severe form of multiorgan failure.

29 ady increase in the prevalence of single and multiorgan failure.

30 dysregulated immune response contributing to multiorgan failure.

31 recipients died because of severe sepsis and multiorgan failure.

32 hondrial and cellular dysfunction leading to multiorgan failure.

33 lead to renal failure and, in severe cases, multiorgan failure.

34 atory derangements, and rapid development of multiorgan failure.

35 f cardiac function and the patient developed multiorgan failure.

36 nd consequently vascular leakage, shock, and multiorgan failure.

37 cularization were performed less commonly in multiorgan failure.

38 stroke causing death, and 1 death following multiorgan failure.

39 to a rapidly fatal meningoencephalitis with multiorgan failure.

40 nt-related death secondary to sepsis-induced multiorgan failure.

41 ignancy, and severe cutaneous reactions with multiorgan failure.

42 scular complications that ultimately promote multiorgan failure.

43 atic disorder leading to heart, and possibly multiorgan failure.

44 opposed, may result in tissue damage or even multiorgan failure.

45 ts/microL and albuminemia <35 g/L) died from multiorgan failure.

46 t who had a combination of syndromes died of multiorgan failure.

47 own origin, complicated by septic shock with multiorgan failure.

48 mortality among critically ill patients with multiorgan failure.

49 AMI VSR is advisable before establishment of multiorgan failure.

50 he patient with single LuTX died from septic multiorgan failure.

51 8 months, with 7 deaths caused by cardiac or multiorgan failure.

52 nd could be responsible for septic shock and multiorgan failure.

53 tant clinical outcomes, such as mortality or multiorgan failure.

54 iated with infection, hepatotoxicity, and/or multiorgan failure.

55 to a sudden loss of hepatic cells leading to multiorgan failure.

56 reas leading causes of death were sepsis and multiorgan failure.

57 underwent liver-lung transplant, one died of multiorgan failure 11 days after transplant compared wit

58 longed aplasia (1), fungal pneumonia (1), or multiorgan failure (2).

59 The most common causes of death were multiorgan failure (26%), hemorrhagic stroke (24%), and

60 was associated with increased postoperative multiorgan failure [42 (35%) vs 56 (20.4%), P = 0.001] a

61 One patient died of multiorgan failure 5 months after transplantation.

62 th (low cardiac output syndrome, 70 [36.5%]; multiorgan failure, 53 [27.6%]).

63 d death (1.1%) occurred in a patient who had multiorgan failure 70 days after the last dose of NIVO p

64 Despite the role of CS in tissue damage and multiorgan failure, a systematic understanding of its un

65 ions (eg, bacteraemia, metastatic infection, multiorgan failure, acute respiratory distress syndrome,

66 fections characterized by rash, hypotension, multiorgan failure and a high mortality rate.

67 Sepsis with multiorgan failure and cerebral oedema remain the leadin

68 e of UGIB in patients under AT are degree of multiorgan failure and comorbidity, but not AT itself.

69 syndrome (SIRS) and the events that lead to multiorgan failure and death are poorly understood.

70 usion that AG 556 prevented cytokine-induced multiorgan failure and death during septic shock by inhi

71 vascular function is crucial for preventing multiorgan failure and death in ischemic and low-pressur

72 ic disease with slow progression, leading to multiorgan failure and death, decades after its first cl

73 s caused by large-scale trauma that leads to multiorgan failure and death, despite the stemming of bl

74 esult in severe neurologic damage as well as multiorgan failure and death.

75 with inflammatory conditions, often leads to multiorgan failure and death.

76 nized as hyperinflammatory states leading to multiorgan failure and death.

77 n, which protects Gaplinc knockout mice from multiorgan failure and death.

78 sease with elevated inflammatory biomarkers, multiorgan failure and death.

79 y mechanical circulatory support may prevent multiorgan failure and death.

80 e can be associated with rapidly progressive multiorgan failure and devastating complications; howeve

81 However, these patients tended to be in multiorgan failure and encephalopathic.

82 reated control animals suffered irreversible multiorgan failure and had to be euthanized within 2 day

83 ukopenia, and thrombocytopenia and developed multiorgan failure and hemorrhage.

84 with excessive immune activation, associated multiorgan failure and high mortality risk.

85 Antithrombin III may provide protection from multiorgan failure and improve survival in severely ill

86 s of severe COVID-19 and are associated with multiorgan failure and increased mortality.

87 ently occurs in critically ill patients with multiorgan failure and is associated with high mortality

88 Acute liver failure (ALF) is associated with multiorgan failure and mortality.

89 %) of 96 in the chemoradiotherapy group (two multiorgan failure and one sepsis).

90 coagulation, and immune systems, leading to multiorgan failure and shock, and thus, in some ways, re

91 iced, survival was related to the absence of multiorgan failure and to higher platelet counts.

92 anada, the United States, and Europe who had multiorgan failure and were receiving mechanical ventila

93 idney injury, cardiac arrhythmias, seizures, multiorgan failure and, rarely, death.

94 1 (2.4%) patient died, 2 (4.9%) experienced multiorgan failure, and 5 (12.2%) had respiratory failur

95 ich is characterized by rashes, hypotension, multiorgan failure, and a high mortality rate.

96 R contributes to early death attributable to multiorgan failure, and an effective treatment has not b

97 d hyperoxia can lead to respiratory failure, multiorgan failure, and death.

98 slocates to the bloodstream, causing sepsis, multiorgan failure, and death.

99 ased susceptibility to secondary infections, multiorgan failure, and death.

100 provokes a potentially fatal pneumonia with multiorgan failure, and high systemic inflammation.

101 eads to acute respiratory distress syndrome, multiorgan failure, and increased mortality.

102 ncreased odds for mortality included sepsis, multiorgan failure, and isolated ileocecal valve involve

103 failure, central nervous system involvement, multiorgan failure, and other manifestations.

104 aracterized by a protracted clinical course, multiorgan failure, and pancreatic necrosis.

105 e inflammatory processes that lead to shock, multiorgan failure, and purpura fulminans in meningococc

106 r Charlson comorbidity index, and those with multiorgan failure, and similar in males and females.

107 organ damage, such as acute chest syndrome, multiorgan failure, and sudden death.

108 vasopressors, which results in hypotension, multiorgan failure, and ultimately patient death.

109 of the recipient, who died 10 weeks later of multiorgan failure, and unusual findings at autopsy.

110 e control group [coronary artery disease and multiorgan failure] and three in the trastuzumab emtansi

111 All died from pulmonary and multiorgan failure around 1 year from onset of the rash.

112 to uncontrolled inflammation, cachexia, and multiorgan failure as seen in the TGF-beta1 null mouse.

113 also contributes to the vascular damage and multiorgan failure associated with severe meningococcal

114 patients with hyperinflammation and evolving multiorgan failure at risk of developing dengue-HLH.

115 Despite multiorgan failure, bacteremia, and disseminated zygomyc

116 Three patients died of progressive multiorgan failure before any treatment was initiated.

117 rally well tolerated, with only 1 death from multiorgan failure before receiving stem cells.

118 verse events, one from dyspnoea and one from multiorgan failure, but neither was treatment related.

119 CSA was greater in patients who experienced multiorgan failure by day 7 (-15.7%; 95% CI, -27.7% to 1

120 an progress to respiratory failure, although multiorgan failure can also occur.

121 by inactivating JNK and p38, thus preventing multiorgan failure caused by exaggerated inflammatory re

122 aphylococcal superantigen-mediated shock and multiorgan failure characteristic of toxic shock.

123 illness and was more severe among those with multiorgan failure compared with single organ failure.

124 ctions associated with early onset shock and multiorgan failure define the streptococcal toxic shock

125 blood pressure </=75 mm Hg) with evidence of multiorgan failure (defined as serum creatinine level >3

126 ing failure, respiratory infections, sepsis, multiorgan failure, durations of stay in the ICU and hos

127 ectively) and a significantly higher rate of multiorgan failure during the entire study (31 vs 17 eve

128 ations (eg, respiratory failure, sepsis, and multiorgan failure), empirical antibiotic therapy in acc

129 cipitating condition and the extent to which multiorgan failure ensues.

130 jury, chronic rejection, biliary sepsis, and multiorgan failure following retransplantation for prima

131 sis with rapidly progressive myocarditis and multiorgan failure from Ehrlichia chaffeensis in a previ

132 nursing home, Intensive care unit admit with multiorgan failure, >=2 Noncancer hospice guidelines) Cr

133 diseases such as bone marrow suppression and multiorgan failure have also been associated with HHV-8.

134 infarction, stroke and pulmonary embolism), multiorgan failure, head injury, and other.

135 however, a prolonged response contributes to multiorgan failure, hypermetabolism, complications, and

136 y failure, respiratory infection, sepsis and multiorgan failure, ICU and hospital length of stay and

137 been a steady increase in the prevalence of multiorgan failure in AMI-CS.

138 y also promote intravascular coagulation and multiorgan failure in animal models.

139 There are limited data on acute noncardiac multiorgan failure in cardiogenic shock complicating acu

140 e response not only causes tissue damage and multiorgan failure in COVID-19 patients but also induces

141 te myocardial infarction in two patients and multiorgan failure in five patients.

142 d lethal hemorrhagic fever with bleeding and multiorgan failure in human patients.

143 ute respiratory distress syndrome (ARDS) and multiorgan failure in patients with coronavirus disease

144 vation of coagulation factor (F) XI promotes multiorgan failure in rodent models of sepsis and in a b

145 esulting vascular injury are responsible for multiorgan failure in sepsis.

146 TGN1412 caused a massive cytokine storm and multiorgan failure in six healthy human volunteers.

147 % TBSA group; p<0.0001), 154 (16%) developed multiorgan failure (increasing from 6% [ten] in the 30-3

148 spitalization, the development of sepsis and multiorgan failure is a harbinger of poor outcome, but t

149 Septicemia with multiorgan failure is associated with chronic activation

150 ential for neurological recovery and ongoing multiorgan failure is warranted for prognostication and

151 risk for systemic sepsis and, in some cases, multiorgan failure leading to death.

152 emic inflammatory response that evolves into multiorgan failure, leading to death.

153 ntation as telomeropathy in adults, in which multiorgan failure may be prominent.

154 (ACLF) is an ailment with high incidence of multiorgan failure (MOF) and consequent mortality.

155 Therefore, single-organ failure and/or multiorgan failure (MOF) are thought to contribute signi

156 e hepatic veno-occlusive disease (sVOD) with multiorgan failure (MOF) in patients who have received c

157 In humans with sepsis, the onset of multiorgan failure (MOF), especially involving liver, lu

158 The most common serious adverse event was multiorgan failure, occurring in 4 patients (2 in each g

159 ; 95% confidence interval: 1.26 to 1.30) and multiorgan failure (odds ratio: 2.23; 95% confidence int

160 developed liver abnormalities and died from multiorgan failure on POD 22.

161 emed treatment-related (pneumonia, two [2%]; multiorgan failure, one [1%]; and sepsis, one [1%], all

162 ochondrial dysfunction can occur and lead to multiorgan failure or death.

163 with persistent liver dysfunction and either multiorgan failure or sepsis at a median of 40 days afte

164 mphohistiocytosis and has been attributed to multiorgan failure or the use of nephrotoxic drugs, but

165 t respiratory distress syndrome (OR = 1.55), multiorgan failure (OR= 1.49), and death (OR = 1.74).

166 eads to a phenotype resembling the premature multiorgan failure phenotype in Klotho-hypomorphic mice

167 ost disease, with the latter associated with multiorgan failure, premature treatment discontinuation,

168 We also evaluated whether evidence of multiorgan failure (requirement for supplemental oxygen,

169 le patient with liver failure also developed multiorgan failure requiring vasopressors, hemodialysis,

170 e to acute respiratory distress syndrome and multiorgan failure resulting in death, especially in ind

171 ic inflammatory response syndrome (SIRS) and multiorgan failure, resulting in high morbidity and mort

172 arrest, severe hemodynamic instability, and multiorgan failure results in poor outcome.

173 one from cerebral lymphoma and the other of multiorgan failure secondary to sepsis.

174 94%), a patient with liver cirrhosis died of multiorgan failure secondary to sodium overload.

175 leeding, need for renal replacement therapy, multiorgan failure, stroke or transient ischemic attack,

176 Hemolytic diseases are frequently linked to multiorgan failure subsequent to vascular damage.

177 825 mg/m2 of paclitaxel; one patient died of multiorgan failure that involved the lung, CNS, and kidn

178 rstitial lung disease and one as a result of multiorgan failure that occurred in the context of infec

179 disease characterized by high inflammation, multiorgan failure, the dysregulation of innate and adap

180 increased risk of cardiovascular events and multiorgan failure, the fundamental mechanisms underlyin

181 llocation policy is needed for patients with multiorgan failure to ensure equitable distribution of t

182 systemic symptoms, lymphadenopathies, and/or multiorgan failure to rapidly document the diagnosis and

183 Presence of multiorgan failure was independently associated with hig

184 ,253 AMI-CS admissions, noncardiac single or multiorgan failure was noted in 32.4% and 31.9%, respect

185 Multiorgan failure was seen more commonly in admissions

186 at model of lipopolysaccharide (LPS)-induced multiorgan failure, we demonstrate that exposure to a lo

187 ular nature, respiratory origin, sepsis, and multiorgan failure were significantly lower in beta-bloc

188 Low cardiac output syndrome and multiorgan failure were the most common causes of death

189 disseminated intravascular coagulation, and multiorgan failure, which all carry poor prognoses.

190 m sinusoidal obstruction syndrome-associated multiorgan failure with Candida sepsis on day +40 follow

191 e of myocarditis, and one patient because of multiorgan failure with Guillain-Barre syndrome.

192 , coagulation abnormalities, hemorrhage, and multiorgan failure with up to 33% case fatality rates (C